SLShiqin Li

Shiqin Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shiqin Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Aroona Razzaq

    Department of Cell Biology School of Life Sciences Central South University Changsha China

    1 shared publication
  • Ashuai Du

    Department of Cell Biology School of Life Sciences Central South University Changsha China

    1 shared publication
  • Cyrollah Disoma

    Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, AREA Science Park, Campus Basovizza, 34149 Trieste, Italy; Doctoral School of Molecular Biomedicine, Department of Life Sciences, University of Trieste, 34149 Trieste, Italy

    1 shared publication
  • Jian Peng

    Department of General Surgery Xiangya Hospital Central South University Changsha China

    1 shared publication
  • Jufang Huang

    Department of Anatomy and Neurobiology School of Basic Medical Sciences Central South University Changsha China

    1 shared publication
  • Liqiang Hu

    The First Hospital of Changsha University of South China Changsha China

    1 shared publication

Latest Publications

  • Open Access

    SARS‐CoV‐2: Mechanism of infection and emerging technologies for future prospects

    by Shiqin Li, Sijia Li, Cyrollah Disoma, Rong Zheng, Mei Zhou, Aroona Razzaq, Pinjia Liu, Yuzheng Zhou, Zijun Dong, Ashuai Du, et al.

    The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread globally to over 200 countries with more than 23 million confirmed cases and at least 800,000 fatalities as of 23 August 2020. Declared a pandemic on March 11 by World Health Organization, the disease caused by SARS‐CoV‐2 infection, called coronavirus disease 2019 (COVID‐19), has become a global public health crisis that challenged all national healthcare systems. This review summarized the current knowledge about virologic and pathogenic characteristics of SARS‐CoV‐2 with emphasis on potential immunomodulatory mechanism and drug development. With multiple emerging technologies and cross‐disciplinary approaches proving to be crucial in our global response against COVID‐19, the application of PROteolysis TArgeting Chimeras strategy, CRISPR‐Cas9 gene editing technology, and Single‐Nucleotide‐Specific Programmable Riboregulators technology in developing antiviral drugs and detecting infectious diseases are proposed here. We also discussed the available but still limited epidemiology of COVID‐19 as well as the ongoing efforts on vaccine development. In brief, we conducted an in‐depth analysis of the pathogenesis of SARS‐CoV‐2 and reviewed the therapeutic options for COVID‐19. We also proposed key research directions in the future that may help uncover more underlying molecular mechanisms governing the pathology of COVID‐19.